3-Bromobenzyl bromide

Names

[ CAS No. ]:
823-78-9

[ Name ]:
3-Bromobenzyl bromide

[Synonym ]:
a,o-dibromotoluene
|A,2-Dibromotoluene
Benzene, 1-bromo-3-(bromomethyl)-
3-Bromobenzyl bromide
m-bromobenzyl bromide
Benzene, 1-bromo-4-(bromomethyl)-
m-BrPhCH2Br
3-Brombenzyl bromide
ortho-bromo benzyl bromide
EINECS 212-519-1
p-Bromobenzyl-bromide
1-Bromo-3-(bromomethyl)benzene
Benzene, 1-bromo-4- (bromomethyl)-
3-BrPhCH2Br
4-Bromobenzyl bromide
3-bromo benzyl bromide
o-Bromobenzyl bromide
ortho-2-bromo-benzyl bromide
α,p-Dibromotoluene
m-Bromobenzyl
2-Bromobenzyl bromide
α,2-Dibromotoluene
Toluene, p,α-dibromo-
BroMobenzyl chloride
1-Bromo-4-(bromomethyl)benzene
MFCD00000176
3-Bromobenzyl bromid

Chemical & Physical Properties

[ Density]:
1.9±0.1 g/cm3

[ Boiling Point ]:
258.2±15.0 °C at 760 mmHg

[ Melting Point ]:
39-41 °C(lit.)

[ Molecular Formula ]:
C₇H₆Br₂

[ Molecular Weight ]:
249.930

[ Flash Point ]:
122.2±19.6 °C

[ Exact Mass ]:
247.883606

[ LogP ]:
3.69

[ Vapour Pressure ]:
0.0±0.5 mmHg at 25°C

[ Index of Refraction ]:
1.606

[ Storage condition ]:
2-8°C

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS05

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H314

[ Precautionary Statements ]:
P280-P305 + P351 + P338-P310

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ Hazard Codes ]:
C:Corrosive;

[ Risk Phrases ]:
R34

[ Safety Phrases ]:
S26-S36/37/39-S45-S25

[ RIDADR ]:
UN 3261 8/PG 2

[ WGK Germany ]:
3

[ Packaging Group ]:
III

[ Hazard Class ]:
8

[ HS Code ]:
29036990

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2903999090

[ Summary ]:
2903999090 halogenated derivatives of aromatic hydrocarbons VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:5.5% General tariff:30.0%

Articles

Distributed Drug Discovery, Part 3: using D(3) methodology to synthesize analogs of an anti-melanoma compound.

J. Comb. Chem. 11(1) , 34-43, (2009)

For the successful implementation of Distributed Drug Discovery (D(3)) (outlined in the accompanying Perspective), students, in the course of their educational laboratories, must be able to reproducib...

Distributed Drug Discovery, Part 2: global rehearsal of alkylating agents for the synthesis of resin-bound unnatural amino acids and virtual D(3) catalog construction.

J. Comb. Chem. 11 , 14-33, (2009)

Distributed Drug Discovery (D(3)) proposes solving large drug discovery problems by breaking them into smaller units for processing at multiple sites. A key component of the synthetic and computationa...

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Bioorg. Med. Chem. Lett. 15(23) , 5241-6, (2005)

The discovery and SAR of a new series of substituted 8-arylquinoline PDE4 inhibitors are herein described. This work has led to the identification of several compounds with excellent in vitro and in v...